NY
NYMXF.US Nymox Pharmaceutical Corporation
- Market cap
- USD 3.68M
- P/E
- -
- P/B
- 44.60x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is NYMXF.US undervalued?
Graham numberThe Graham number of Nymox Pharmaceutical Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nymox Pharmaceutical Corporation fundamental analysis
No fundamental analysis for Nymox Pharmaceutical Corporation yet.
Nymox Pharmaceutical Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low-grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert, a simple, cost-effective test for determining smoking status; and TobacAlert, a test for detecting second-hand smoke …
Full company profileNymox Pharmaceutical Corporation financial statements
Nymox Pharmaceutical Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 116K | 5.00K | -5.00K | -5.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 49.0K | -8.00K | -12.0K | -12.0K | -11.0K | 0.00 | - |
| Operating Income | -13.3M | -11.7M | -12.5M | -6.65M | -8.35M | -4.28M | -3.68M |
| EBITDA | -13.3M | -11.7M | -12.5M | -6.52M | -8.77M | -4.27M | -3.56M |
| Net Income | -13.2M | -11.7M | -12.5M | -6.58M | -8.84M | -4.49M | -4.28M |
| EPS | -0.19 | -0.16 | -0.15 | -0.07 | -0.10 | -0.05 | - |
| Balance Sheet | |||||||
| Total Assets | 6.08M | 4.93M | 2.03M | 1.63M | 627K | 654K | 576K |
| Total Liabilities | 2.04M | 2.20M | 1.95M | 2.11M | 3.80M | 7.43M | 9.88M |
| Shareholders' Equity | 4.04M | 2.73M | 83.0K | -482K | -3.17M | -6.78M | -9.31M |
| Cash & Short-term Investments | 5.24M | 3.61M | 830K | 1.40M | 70.0K | 74.0K | 6.00K |
| Total Debt | 147K | 426K | 391K | 173K | 750K | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -7.43M | -10.0M | -9.82M | -5.21M | -4.06M | -2.60M | -1.81M |
| Capital Expenditure | 13.0K | 13.0K | 6.00K | 0.00 | 3.00K | 0.00 | 1.00K |
| Free Cash Flow | -7.43M | -10.1M | -9.83M | -5.21M | -4.06M | -2.60M | -1.81M |
| Ratios | |||||||
| ROE | -326.0% | -429.3% | -15,104.8% | - | - | - | - |
| ROA | -216.6% | -238.0% | -617.0% | -404.7% | -1,410.5% | -686.9% | -742.2% |
| Net Profit Margin | -11,346.6% | -234,760.0% | - | - | - | - | - |
| Debt to Equity | 0.04x | 0.16x | 4.71x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nymox Pharmaceutical Corporation dividends
Nymox Pharmaceutical Corporation has not paid dividends in the last 9 fiscal years.
Who owns Nymox Pharmaceutical Corporation
- Insiders 48.60%
- Institutions 0.04%
- Public & others 51.36%
- Shares outstanding 105M
- Free float 60.7M
Nymox Pharmaceutical Corporation company profile
- Company name
- Nymox Pharmaceutical Corporation
- Ticker
- NYMXF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- Bay & Deveaux Streets, Nassau, Bahamas
- Phone
- 800 936 9669
- Website
- nymox.com
About Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low-grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert, a simple, cost-effective test for determining smoking status; and TobacAlert, a test for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment and prevention of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.
Nymox Pharmaceutical Corporation management
2- Dr. Paul Averback DABP, M.D.Founder, Chairman, CEO & President · born 1951
- Ms. Lin DoddQA and Compliance Manager